Unichem Laboratories
Ticker > Company >

Unichem Laboratories share price

Unichem Laboratories Ltd.

NSE: UNICHEMLAB BSE: 506690 SECTOR: Pharmaceuticals & Drugs  46.62 K   43   7

528.55
-58.45 (-9.96%)
NSE: 22 Jul 4:00 PM

Price Summary

Today's High

₹ 586.95

Today's Low

₹ 528.3

52 Week High

₹ 687.2

52 Week Low

₹ 278.2

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 3721.3 Cr.

Enterprise Value

₹ 3516.75 Cr.

No. of Shares

7.04 Cr.

P/E

23.41

P/B

1.42

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  372.3

CASH

₹ 257.89 Cr.

DEBT

₹ 53.34 Cr.

Promoter Holding

70.22 %

EPS (TTM)

₹  22.57

Sales Growth

-18.63%

ROE

6.26 %

ROCE

8.43%

Profit Growth

-2.47 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-18.63%
3 Year9.61%
5 Year4.67%

Profit Growth

1 Year-2.47%
3 Year36.27%
5 Year24.06%

ROE%

1 Year6.26%
3 Year3.06%
5 Year-0.96%

ROCE %

1 Year8.43%
3 Year4.26%
5 Year-0.1%

Debt/Equity

0.0203

Price to Cash Flow

70.75

Interest Cover Ratio

18.7466

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 70.22 0.00
Mar 2026 70.22 0.00
Dec 2025 70.22 0.00
Sep 2025 70.22 0.00
Jun 2025 70.22 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 57.71 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 18.7466.
  • Company has a healthy liquidity position with current ratio of 4.8693.
  • The company has a high promoter holding of 70.22%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 5.83259088240225.

 Limitations

  • The company has shown a poor revenue growth of 9.61019433243904% for the Past 3 years.
  • Company has a poor ROE of 3.0589% over the past 3 years.
  • Company has a poor ROCE of 4.25696666666667% over the past 3 years
  • Company has contingent liabilities of 631.07 Cr.
  • The company has a low EBITDA margin of 1.68801956844997% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 31.3206.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 461.24 384.25 356.9 314.9 356.24
Total Expenditure 386.26 358.51 349.2 313.51 343.75
Operating Profit 74.98 25.74 7.7 1.39 12.49
Other Income 6.05 4.25 21.4 15.03 22.22
Interest 1.53 1.93 3.68 2.1 4.09
Depreciation 27.47 29.93 30.11 30.02 28.97
Exceptional Items 4 0 -33.14 275.52 -12.36
Profit Before Tax 56.03 -1.87 -37.83 259.82 -10.71
Tax 4.81 -0.02 2.1 43.71 4.68
Profit After Tax 51.22 -1.85 -39.93 216.11 -15.39
Adjusted EPS (Rs) 7.28 -0.26 -5.67 30.7 -2.19

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 942.93 1072.43 1442.16 1735.7 1412.29
Total Expenditure 986.48 1165.35 1391.25 1481.82 1361.93
Operating Profit -43.55 -92.91 50.91 253.88 50.36
Other Income 42.07 41.85 30.39 40.83 62.9
Interest 2.07 9.38 10.42 7.62 11.8
Depreciation 83.19 105.98 105.45 108.41 119.03
Exceptional Items 0 -112.66 -57.61 4 226.98
Profit Before Tax -86.75 -279.09 -92.18 182.68 209.41
Tax -31.32 20.61 0 19.72 50.47
Net Profit -55.43 -299.7 -92.18 162.96 158.94
Adjusted EPS (Rs.) -7.87 -42.57 -13.09 23.15 22.58

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 14.08 14.08 14.08 14.08 14.08
Total Reserves 2657.96 2370.19 2280.55 2445.67 2613.02
Borrowings 89.01 63.65 38.22 60.81 39.12
Other N/C liabilities 50.62 49.56 42.91 69.12 111.27
Current liabilities 310.42 388.66 465.75 519.53 314.96
Total Liabilities 3122.08 2886.14 2841.51 3109.21 3092.45
Assets
Net Block 963.12 1235.94 1164.94 1274.69 1189.48
Capital WIP 494.18 147.82 122.36 31.03 100.5
Intangible WIP 0 0 0 0 0
Investments 126.22 38.98 42.74 45.62 47.49
Loans & Advances 164.61 167.22 124.18 182.01 218.08
Other N/C Assets 3.47 3.41 3.35 9.52 3.25
Current Assets 1370.49 1292.76 1383.94 1566.34 1533.65
Total Assets 3122.08 2886.14 2841.51 3109.21 3092.45
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations -86.75 -279.09 -92.18 182.68 209.41
Adjustment 72.2 203.3 165.38 107.3 -127.16
Changes in Assets & Liabilities -147.82 -41.45 -114.62 -217.41 -29.99
Tax Paid 4.06 -0.09 -0.15 -0.28 0.34
Operating Cash Flow -158.31 -117.33 -41.57 72.29 52.6
Investing Cash Flow 104.03 240.63 59.61 -175.62 210.15
Financing Cash Flow 95.8 -61.76 -48.06 38.26 -70.66
Net Cash Flow 41.53 61.54 -30.02 -65.07 192.09

Corporate Actions

Investors Details

PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
promoters 70.22 70.22 70.22 70.22 70.22
anita prakash mody 1.88 1.88 1.88 1.88 1.88
dr. prakash amrut mody 12.78 12.78 12.78 12.78 12.78
dr. prakash amrut mody - ... 0.06 0.06 0.06 0.06 0.06
dr. prakash amrut mody - ... 0.07 0.07 0.07 0.07 0.07
dr. prakash amrut mody - ... 0.06 0.06 0.06 0.06 0.06
ipca laboratories limited... 52.67 52.67 52.67 52.67 52.67
suparna prakash mody 1.35 1.35 1.35 1.35 1.35
supriya prakash mody 1.35 1.35 1.35 1.35 1.35
PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
investors 29.78 29.78 29.78 29.78 29.78
dsp healthcare fund 1.21 1.21 1.21 1.21 1.56
hdfc small cap fund 7.75 7.75 7.75 7.75 7.75
investor education and pr... 1.06 1.09 1.09 1.07 1.04
llp 0.07 0.02 0.02 0.03 0.03
investor education and pr... 1.06 1.09 1.09 1.07 1.04

Annual Reports

Title Link
Title Link
Annual Report 2026
Annual Report 2025
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ICRA
Credit ICRA
Credit ICRA
Credit ICRA
Credit ICRA
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY17
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY17

Company News

 No Latest News available for this company.Report us

Unichem Laboratories Stock Price Analysis and Quick Research Report. Is Unichem Laboratories an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Unichem Laboratories. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Unichem Laboratories has a PE ratio of 23.413171265432 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Unichem Laboratories has ROA of 5.1257% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Unichem Laboratories has a Current ratio of 4.8693.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Unichem Laboratories has a ROE of 6.2627%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Unichem Laboratories has a Debt to Equity ratio of 0.0203 which means that the company has low proportion of debt in its capital.

  • Sales growth: Unichem Laboratories has reported revenue growth of -18.6328% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Unichem Laboratories for the current financial year is 3.56583987707906%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Unichem Laboratories is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Unichem Laboratories is Rs 22.5749. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Unichem Laboratories in Ticker for free. Also, one can get the intrinsic value of Unichem Laboratories by using Valuation Calculators, which are available with a Finology ONE subscription. 

Unichem Laboratories FAQs

Q1. What is Unichem Laboratories share price today?
Ans: The current share price of Unichem Laboratories is Rs 528.55.

Q2. What is the market capitalisation of Unichem Laboratories?
Ans: Unichem Laboratories has a market capitalisation of Rs 3721.295969105 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Unichem Laboratories?
Ans: The PE ratio of Unichem Laboratories is 23.413171265432 and the P/B ratio of Unichem Laboratories is 1.41970749002807, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Unichem Laboratories share?
Ans: The 52-week high share price of Unichem Laboratories is Rs 687.2, and the 52-week low share price of Unichem Laboratories is Rs 278.2.

Q5. Does Unichem Laboratories pay dividends?
Ans: Currently, Unichem Laboratories does not pay dividends. Dividend yield of Unichem Laboratories is around 0%.

Q6. What are the face value and book value of Unichem Laboratories shares?
Ans: The face value of Unichem Laboratories shares is Rs 2, while the book value per share of Unichem Laboratories is around Rs 372.295. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Unichem Laboratories?
Ans: Unichem Laboratories has a total debt of Rs 53.34 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Unichem Laboratories?
Ans: The ROE of Unichem Laboratories is 6.2627% and ROCE of Unichem Laboratories is 8.4251%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Unichem Laboratories a good buy for the long term?
Ans: The Unichem Laboratories long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Unichem Laboratories undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Unichem Laboratories appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Unichem Laboratories’s financials?
Ans: You can review Unichem Laboratories’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Unichem Laboratories

Unichem Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Unichem Laboratories Ltd. is a leading pharmaceutical company that specializes in the manufacturing and marketing of generic pharmaceuticals. With a strong presence in domestic and international markets, Unichem has established itself as a trusted name in the healthcare sector. The company was founded in 1944 and has since grown to become one of the key players in the pharmaceutical industry.

Share Price Analysis - Unichem Laboratories Ltd.

Unichem Laboratories Ltd.'s share price is an important parameter for investors looking to assess the company's performance in the stock market. Our pre-built screening tools provide an in-depth analysis of the company's share price history, enabling long-term investors to make informed decisions. The share price is influenced by various factors, including market trends, company performance, and industry outlook.

Balance Sheet Analysis - Unichem Laboratories Ltd.

Unichem Laboratories Ltd.'s balance sheet is a key financial statement that provides insights into the company's financial health. Our premium features, such as our fair value calculation tools, including DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, assist investors in evaluating the company's balance sheet. This allows investors to assess the company's financial stability and make informed investment decisions.

Annual Report - Unichem Laboratories Ltd.

The annual report of Unichem Laboratories Ltd. is a comprehensive document that provides a detailed overview of the company's performance and financial statements for the fiscal year. Investors can download the annual reports from our website to gain a deeper understanding of the company's strategies, operations, and future prospects.

Dividend Analysis - Unichem Laboratories Ltd.

Dividends are an important aspect for long-term investors. Unichem Laboratories Ltd. provides regular dividend payouts to its shareholders. By analyzing the company's dividend history, investors can assess the company's dividend policy, sustainability, and potential growth. Our pre-built screening tools help investors track dividend payouts and make informed investment decisions.

Quarterly Result Analysis - Unichem Laboratories Ltd.

Unichem Laboratories Ltd.'s quarterly results provide a snapshot of the company's financial performance during a specific period. Investors can download the quarterly results from our website to analyze key financial metrics and assess the company's growth trajectory. Our premium features, such as fair value calculation tools, provide an in-depth analysis of the quarterly results, allowing investors to evaluate the company's financial performance.

Stock Price Analysis - Unichem Laboratories Ltd.

Unichem Laboratories Ltd.'s stock price is determined by various factors, including market dynamics, investor sentiment, and company-specific factors. Our pre-built screening tools provide an analysis of the company's stock price history, allowing investors to identify trends and patterns. This analysis helps long-term investors gain insights into the company's stock price and make informed investment decisions.

Price Chart Analysis - Unichem Laboratories Ltd.

The price chart of Unichem Laboratories Ltd. provides an overview of the company's stock price movement over a specific period. Our pre-built screening tools offer interactive price charts that help investors track the company's stock price performance, identify support and resistance levels, and analyze trends. This analysis assists long-term investors in understanding the stock's historical performance and making informed investment decisions.

News and Updates - Unichem Laboratories Ltd.

Staying updated with the latest news and updates about Unichem Laboratories Ltd. is crucial for investors. Our website provides curated news articles, press releases, and market updates related to the company. These resources help investors stay informed about key developments, industry trends, and regulatory changes that may impact the company's performance.

Conference Call Transcripts - Unichem Laboratories Ltd.

Conference call transcripts provide insights into the discussions and decisions made during the company's quarterly or annual conference calls. Investors can download the conference call transcripts from our website to gain a deeper understanding of management's perspective on the company's performance, growth strategy, and future outlook. These transcripts serve as valuable resources for long-term investors looking for a comprehensive analysis.

Investor Presentations - Unichem Laboratories Ltd.

Investor presentations offered by Unichem Laboratories Ltd. provide a detailed overview of the company's business model, growth strategy, financial performance, and future outlook. Investors can download these presentations from our website to gain insights directly from the company. These presentations help investors understand the company's value proposition, innovative initiatives, and competitive advantage in the pharmaceutical industry.

Promoters and Shareholders - Unichem Laboratories Ltd.

Unichem Laboratories Ltd.'s promoters and shareholders play a crucial role in shaping the company's operations and growth. Our website provides information about the company's promoters and major shareholders, helping investors gain insights into the management's expertise, experience, and long-term vision. This information is valuable for investors looking to assess the credibility and stability of the company's ownership structure.

In conclusion, Unichem Laboratories Ltd. offers a comprehensive stock analysis page that caters to the needs of long-term stock investors. With a focus on providing relevant and accurate information, our website equips investors with the necessary tools to analyze the company's performance and make informed investment decisions. Our pre-built screening tools and premium features, such as fair value calculation tools, provide investors with valuable insights into various aspects of Unichem Laboratories Ltd.'s stock. Downloadable resources, including annual reports, conference call transcripts, and investor presentations, enable investors to delve deeper into the company's strategies and future prospects. Stay updated with the latest news and updates to stay informed about key developments in the pharmaceutical industry. Happy investing!   

Unichem Laboratories Equity and Liabilities Analysis

Examining Unichem Laboratories' balance sheet data showcases the stability and changes within the company's equity and liabilities over a span of five years. As of March 2024, the share capital has remained constant at Rs 14.08 Cr, reflecting stability in the company's equity structure. A close inspection reveals a decline in total reserves, from Rs 2,633.10 Cr in March 2020 to Rs 2,280.54 Cr by March 2024, raising questions about retained earnings and appropriations.

Unichem Laboratories Borrowings and Current Liabilities Insights

A noteworthy development in Unichem Laboratories' financials is the introduction of borrowings in March 2022, initially recorded at Rs 89.01 Cr and being progressively reduced to Rs 38.22 Cr by March 2024. This suggests a responsible approach towards debt management. The increase in current liabilities from Rs 348.27 Cr in March 2020 to Rs 487.94 Cr in March 2024, potentially indicates expanded operations or increased short-term obligations.

Unichem Laboratories Asset Allocation Over the Years

On the assets front, Unichem Laboratories has seen a substantial rise in its net block, from Rs 824.94 Cr in March 2020 to Rs 1,235.94 Cr in March 2023, before a slight drop to Rs 1,164.94 Cr in March 2024, hinting at significant capital expenditure and subsequent depreciation. Current assets saw a dip in March 2021 but have risen since, reaching Rs 1,406.13 Cr by March 2024, which could reflect an increase in inventory or receivables.

This data represents an analysis for the Standalone Balance Sheet of the company.

In assessing Unichem Laboratories' financial health, investors might also consider broader market trends, such as NSE/BSE indices, which can offer insights into how sectoral shifts might impact the company's performance. 

Unichem Laboratories Balance Sheet Analysis

Unichem Laboratories Share Capital

Unichem Laboratories has maintained its share capital consistently at Rs 14.08 Cr from March 2020 through to March 2024. This stability signifies a constant equity base over the years.

Unichem Laboratories Reserves

The company's total reserves have seen fluctuations, starting at Rs 2,633.10 Cr in March 2020, peaking in March 2021 at Rs 2,683.25 Cr, and experiencing a gradual decline to Rs 2,280.54 Cr by March 2024. The dwindling reserves indicate a decrease in retained earnings over the recent years.

Unichem Laboratories Borrowings

Initially, Unichem Laboratories reported zero borrowings up to March 2021 but then recorded an increase in March 2022 to Rs 89.01 Cr, which has been decreasing over subsequent years to Rs 38.22 Cr by March 2024. This shows a cautious approach towards leveraging.

Unichem Laboratories Assets Overview

The net block and capital work in progress (WIP) signify the company's investment in tangible assets and future projects. With the net block value rising from Rs 824.94 Cr in March 2020 to Rs 1,164.94 Cr in March 2024, it reflects ongoing and completed capital expenditures. However, capital WIP has decreased from its peak in March 2021 at Rs 567.73 Cr to Rs 122.36 Cr by March 2024, indicating a slowdown in new projects.

Unichem Laboratories Current Assets and Liabilities

Current assets have seen a varied trend, with an initial decrease in March 2021, followed by fluctuations, ultimately resulting in an increase to Rs 1,406.13 Cr by March 2024. Current liabilities have gradually increased throughout the period, pointing to a rise in short-term obligations.

This data presents a standalone balance sheet analysis for Unichem Laboratories, crucial for investors examining the financial health and operational efficiency of the company.

In the landscape of stock screening and investment, understanding such detailed balance sheet dynamics helps investors in making informed decisions not just in pharmaceutical sectors but across various sectors listed on NSE BSE indices and potential IPOs.

Read More
X